$34.47
1.29% yesterday
Nasdaq, May 20, 10:13 pm CET
ISIN
US4622221004
Symbol
IONS
Sector
Industry

Ionis Pharmaceuticals, Inc. Stock price

$34.47
+5.96 20.90% 1M
-0.93 2.63% 6M
-0.49 1.40% YTD
-4.25 10.98% 1Y
-5.02 12.71% 3Y
-19.75 36.43% 5Y
-33.09 48.98% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.44 1.29%
ISIN
US4622221004
Symbol
IONS
Sector
Industry

Key metrics

Market capitalization $5.49b
Enterprise Value $5.30b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 7.38
P/S ratio (TTM) P/S ratio 7.64
P/B ratio (TTM) P/B ratio 11.52
Revenue growth (TTM) Revenue growth -7.65%
Revenue (TTM) Revenue $717.68m
EBIT (operating result TTM) EBIT $-471.61m
Free Cash Flow (TTM) Free Cash Flow $-555.15m
Cash position $2.15b
EPS (TTM) EPS $-2.98
P/E forward negative
P/S forward 7.53
EV/Sales forward 7.27
Short interest 10.72%
Show more

Is Ionis Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Ionis Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast:

19x Buy
68%
8x Hold
29%
1x Sell
4%

Analyst Opinions

28 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast:

Buy
68%
Hold
29%
Sell
4%

Financial data from Ionis Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
718 718
8% 8%
100%
- Direct Costs 32 32
0% 0%
5%
685 685
8% 8%
95%
- Selling and Administrative Expenses 248 248
27% 27%
34%
- Research and Development Expense 888 888
3% 3%
124%
-450 -450
23% 23%
-63%
- Depreciation and Amortization 22 22
4% 4%
3%
EBIT (Operating Income) EBIT -472 -472
21% 21%
-66%
Net Profit -458 -458
19% 19%
-64%

In millions USD.

Don't miss a Thing! We will send you all news about Ionis Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ionis Pharmaceuticals, Inc. Stock News

Neutral
Business Wire
one day ago
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the Essence study of olezarsen in people with moderate hypertriglyceridemia (fasting triglycerides ≥150 mg/dL to
Neutral
Business Wire
15 days ago
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2025 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 5, 2025. The agenda for the event is as follows: 5:00 p.m. – 5:15 p.m. ET (2:00 p.m. – 2:15 p.m. PT) – Virtual Annual Meeting of Stockholders All stockholders of record ...
Neutral
Seeking Alpha
20 days ago
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q1 2025 Earnings Conference Call April 30, 2025 11:30 AM ET Company Participants Wade Walke - SVP, IR Brett Monia - Founder, CEO & Director Kyle Jenne - EVP & Chief Global Product Strategy Officer Beth Hougen - EVP, Finance & CFO Jonathan Birchall - SVP & Chief Commercial Officer Eugene Schneider - EVP, Chief Clinical Development & Operations Officer C...
More Ionis Pharmaceuticals, Inc. News

Company Profile

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Head office United States
CEO Brett Monia
Employees 1,069
Founded 1989
Website www.ionis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today